NDA 020992 · Aspen
Cenestin
Estrogens, Conjugated Synthetic A · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Mar 24, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
1,166
241 Phase 3, 150 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 5, 2004 Supplement 21 · Efficacy LetterLabel
- Jun 21, 2002 Supplement 16 · Efficacy LabelReviewLetter
- Mar 24, 1999 Original approval · Type 3 - New Dosage Form LabelReviewLetter
5 products under this application
- CENESTIN · ESTROGENS, CONJUGATED SYNTHETIC A 0.45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- CENESTIN · ESTROGENS, CONJUGATED SYNTHETIC A 0.9MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- CENESTIN · ESTROGENS, CONJUGATED SYNTHETIC A 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- CENESTIN · ESTROGENS, CONJUGATED SYNTHETIC A 1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- CENESTIN · ESTROGENS, CONJUGATED SYNTHETIC A 0.625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Estrogens" as an intervention, any sponsor and status, largest first.
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
The Third Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07421908 · 5,000 participants (planned) · Start Mar 1, 2025 · Primary completion Mar 1, 2030
Drug: Traditional Chinese medicine for tonifying the kidney · For: Intrauterine Adhesion
Sites: Changsha, China
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePivotal-lookingActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT06492616 · 4,556 participants · Start Sep 27, 2024 · Primary completion Aug 2029
Drug: Elacestrant; Anastrozole and 3 more · For: Breast Cancer
Sites: Daphne, Alabama; Chandler, Arizona; Gilbert, Arizona · 555 sites in all
- Trial of Perioperative Endocrine Therapy - Individualising CarePivotal-lookingActive, not recruiting
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT02338310 · 4,486 participants · Start Sep 2008 · Primary completion Apr 2024
Drug: Aromatase Inhibitors · For: Breast Cancer
Sites: Dundonald, United Kingdom; Slough, United Kingdom; Aylesbury, United Kingdom · 128 sites in all
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05774951 · 4,300 participants (planned) · Start Mar 31, 2023 · Primary completion Apr 20, 2027
Drug: Camizestrant; Tamoxifen and 3 more · For: Breast Cancer, Early Breast Cancer
Sites: Birmingham, Alabama; Dothan, Alabama; Anchorage, Alaska · 709 sites in all
- Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT01547741 · 4,242 participants · Start Apr 2012 · Primary completion May 31, 2022
Drug: Doxorubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 915 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Estrogen Deficiency and the Origin of Obesity during Menopause.
Lizcano F, Guzmán G · Biomed Res Int 2014 · Systematic Review
- Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition.
Andy C, Nerattini M, Jett S, et al. · Front Endocrinol (Lausanne) 2024 · Meta-Analysis, Systematic Review
- Treatment of urge incontinence in postmenopausal women: A systematic review.
Bapir R, Bhatti KH, Eliwa A, et al. · Arch Ital Urol Androl 2023 · Meta-Analysis, Systematic Review
- Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR, Monteleone P, Giannini A, et al. · Hum Reprod Update 2021 · Randomized Controlled Trial
- Estrogen for schizophrenia.
Chua WL, de Izquierdo SA, Kulkarni J, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Supplementation with a Probiotic Formula Having β-Glucuronidase Activity Modulates Serum Estrogen Levels in Healthy Peri- and Postmenopausal Women.
Honda S, Tominaga Y, Espadaler-Mazo J, et al. · J Med Food 2024 · Randomized Controlled Trial
Sponsor: Aspen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.